Digital Experiences, Product Differentiation, and Wearables Drive Consumer Luxury Spending

 

According to the 2023 PWC Global Consumer Insights Pulse Survey, 63% of consumers are holding back on non-essential spending. According to a Criteo survey, despite consumers general reluctance to spend, luxury spending is on the rise. The survey found that 70% of high-income shoppers are spending the same or more on luxury goods while 54% of low- to middle-income shoppers have similar plans to do the same.

Luxury brands are now more accessible to consumers through various means including social media and other digital advertising channels. A report by Bain & Co. found that the luxury brands in Europe and the United States saw positive growth in 2022 and projected that the luxury market will reach roughly $1.45 trillion by the end of that year.

However, things may slow down, according to a PWC Consumer Insights Survey. Luxury/premium products, travel, and fashion are expected to be hit the hardest over the next six months. However, the survey also found that there still is an appetite for future spending. 40% of consumers indicate they will look to treat themselves and others with luxury items while 39% view luxury items as better quality items.

With so many predictions for growth and decline, what is driving the increase in luxury spending and will consumers continue to spend on luxury goods as time goes on? Jennifer Meresca, COO for Genpact Consumer & Healthcare Consulting Division, has been watching these trends closely for the last several months. Here’s her assessment of the luxury spending’s outlook for 2023, as well as what’s motivating this uptick in consumer spending.

Jennifer‘s Thoughts

“Luxury retail continues to anticipate a 3% to 8% growth in 2023. We are tracking key trends with our clients and their customers that are driving this outlook. Given the continued interest in luxury goods, despite global economic pressures, brands are expanding their customer base through channels such as digital and metaverse experiences, product differentiation through accessories, and focus on healthcare through luxury wearable technology.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More